Chapel Hill, NC (September 9, 2015) – Rho, a contract research organization (CRO) providing clinical research services in both the commercial and federal market, has been awarded a new cooperative agreement to provide statistical and clinical coordinating services to the Division of Allergy, Immunology and Transplantation (DAIT), National Institute of Allergy and Infectious Diseases (NIAID). The NC-based CRO will provide these services for DAIT’s large clinical research consortia in the areas of asthma and allergic diseases, autoimmune diseases, and transplantation.
The largest federal contract in Rho’s 31-year history, the award is valued at approximately $16.5 million per year for seven years. Additionally, supplemental funds of approximately $6.8 million have been awarded for the first year.
“Rho is excited to be selected as DAIT’s Statistical and Clinical Coordinating Center to support the important work they are doing to help combat serious health concerns, such as asthma and allergies, autoimmune diseases, and transplantation,” said Russ Helms, Ph.D., Chief Executive Officer for Rho. “Rho’s expertise and resources will help assure top-notch operational support, statistical analysis, clinical data management and bioinformatics services.”
The program uses a multiple principal investigator (PI) structure. Five Rho employees are serving as PIs on this project, including: Ronald W. Helms, Ph.D., Chairman and overall PI; Karen Kesler, Ph.D., Senior Statistical Scientist and Leadership Group PI; Samuel Arbes, Jr., D.D.S., M.P.H., Ph.D., Senior Research Scientist and Group Leader for the Asthma and Allergic Diseases Group; David Ikle, Ph.D., Senior Statistical Scientist and Group Leader for the Transplantation Group; and Lynette Keyes-Elstein, DrPH, Senior Statistical Scientist and Group Leader for the Autoimmune Diseases Group. Additionally, day-to-day management will be provided by Michelle Walter, M.S., Senior Project Director.
The project combines services that were previously under six separate awards from DAIT – Rho held five of the previous awards. For additional details about Rho’s federal research expertise, visit www.rhoworld.com/rho/federal-research.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Twice-Yearly Lenacapavir Injections Significantly Reduce HIV Risk, PURPOSE 2 Trial Shows
November 13th 2024Full Phase III PURPOSE 2 trial results suggest that twice-yearly lenacapavir could revolutionize HIV prevention by offering a convenient and effective long-acting option for individuals at risk of infection.